๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis

โœ Scribed by Aysegul Atmaca; Olcay Gedik

Publisher
Springer Healthcare Communications
Year
2006
Tongue
English
Weight
279 KB
Volume
23
Category
Article
ISSN
0741-238X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Effects of bazedoxifene on bone mineral
Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis
โœ Akira Itabashi; Kousei Yoh; Arkadi A Chines; Takami Miki; Masahiko Takada; Hiros ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American Society for Bone and Mineral Research ๐ŸŒ English โš– 244 KB ๐Ÿ‘ 2 views

## Abstract This randomized, doubleโ€blind, placeboโ€controlled, doseโ€response late phase 2 study evaluated the efficacy and safety of bazedoxifene in postmenopausal Japanese women 85 years of age or younger with osteoporosis. Eligible subjects received daily treatment with oral doses of bazedoxifene

Effects of denosumab on bone turnover ma
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
โœ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American Society for Bone and Mineral Research ๐ŸŒ English โš– 272 KB ๐Ÿ‘ 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumabโ€treat